Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
2023The Lancet Respiratory MedicineJournalOpen access
10.1016/s2213-2600(23)00263-1Full text25 citations